Brien G, Bick C
Eur Urol. 1977;3(1):35-6. doi: 10.1159/000472051.
Since 1973 we have used allopurinol in the prevention and aftercare of recurrent urolithiasis. We give indications for the administration of allopurinol for patients with chronically recurring calcium oxalate lithiasis. Special attention is given to the urinary stone analysis as well as to metabolic disorders as for example hyperuricaemia, hyperuricuria or idiopathic hypercalciuria. In 15 patients with calcium oxalate lithiasis the stone/patient/year ratio could be decreased to 38%. In 19 patients with uric acid/calcium oxalate calculi or alternating stone formations from uric acid and calcium oxalate we succeeded in decreasing this ratio from 1.72 to 0.47 or 27%.
自1973年以来，我们一直使用别嘌醇预防复发性尿路结石并进行后续护理。我们给出了别嘌醇用于慢性复发性草酸钙结石患者的用药指征。特别关注尿液结石分析以及代谢紊乱，如高尿酸血症、高尿酸尿症或特发性高钙尿症。在15例草酸钙结石患者中，结石/患者/年的比例可降至38%。在19例尿酸/草酸钙结石或尿酸和草酸钙交替形成结石的患者中，我们成功地将这一比例从1.72降至0.47，即27%。
